| Literature DB >> 34775848 |
Catriona Ida Macleod1, John Hunter Reynolds2.
Abstract
OBJECTIVES: Women who sell sex have a high prevalence of human papilloma virus, which may cause cervical cancer. The objective of this review was to collate findings on prevalence, associated factors, screening, service provision and utilization of services in relation to human papilloma virus and cervical cancer among women who sell sex in Eastern and Southern Africa.Entities:
Keywords: Africa; Eastern Africa; HPV; Human Papilloma Virus; Southern Africa; cervical cancer; review; sex workers
Mesh:
Year: 2021 PMID: 34775848 PMCID: PMC8593294 DOI: 10.1177/17455065211058349
Source DB: PubMed Journal: Womens Health (Lond) ISSN: 1745-5057
Figure 1.PRISMA diagram.
Summary of studies.
| Citation | Study aims | Major findings | Study recommendations |
|---|---|---|---|
| Location | |||
| Programme | Data collection | ||
| Study population | |||
| Afzal et al.
| Address barriers to cervical cancer treatment, a “see and treat” approach to screening was proposed. The objective was to integrate this method into current HIV care offered by local providers and to obtain demographic and risk factor data for use in future educational and intervention programmes in the region. | A total of 403 participants consented and underwent screening with VIA (306 farm workers and 97 sex workers participated). 83.9% of participants (32.9% sex workers and 100% farm workers) were HIV+. VIA was positive in 30.5% of participants, necessitating cryotherapy. There was no significant difference in VIA positivity between HIV+ farm workers and sex workers. There was a positive correlation between Pap smears and VIAs results. | The study demonstrates successful integration of cervical cancer screening using VIA for HIV+ farm workers and sex workers into an existing HIV treatment and prevention clinic in rural South Africa, addressing and treating abnormal results promptly. An improved infrastructure and referral process for these rural and high-risk populations is still a highly unaddressed need. |
| South Africa | |||
| “See and treat” approach to screening at an HIV clinic | Screening results using visual inspection with acetic acid (VIA), and Pap smear results for the previous year at the time of programme initiation and at 12 and 18 months post-programme | ||
| HIV farm workers and at-risk sex workers attending a clinic | |||
| Auvert et al.
| Assess HPV as a risk factor of HIV acquisition among FSWs in South Africa. | HR- and LR-HPV prevalences were 70.5% (95% CI: 60.5–79.2) and 60.2% (95% CI: 49.9–70.0), respectively. Twenty-five women HIV seroconverted. Controlling for background characteristics and other sexually transmitted infections, HIV aHR increased by a factor of 1.7 (95% CI: 1.01–2.7, Plinear trend = 0.045) for an increase of one unit of the number of HR-HPV genotypes. HIV seroconversion among FSWs is associated with genital HR-HPV infection. Further investigation is warranted, including testing the possible protective effect of available HPV vaccines on HIV acquisition. | Despite these limitations, these findings indicate that the hypothesis of a facilitating effect of HR-HPV on HIV acquisition requires further investigation using longitudinal data. The validation of this hypothesis could necessitate testing the potential protective effect of available HPV vaccines on HIV acquisition. |
| South Africa | |||
| Multicentre, randomized, placebo-controlled, triple-blinded, phase 2/3 efficacy trial of COL-1492, a low-dose nonoxynol-9 microbicide | Cervicovaginal rinse samples, obtained before HIV-seroconversion, were genotyped into high-risk (HR-) and low-risk (LR-) HPV. HIV-adjusted hazard ratios (aHRs) and 95% confidence intervals (CI) were estimated using Cox survival analysis. | ||
| Non drug using, not pregnant, HIV-negative South African FSWs working at truck stops along a major highway | |||
| Cameron et al.
| Examine the association between cervical Epstein-Barr virus (EBV), high risk HPV (hrHPV) and cytology in female sex workers | Baseline prevalence of hrHPVand EBV was 29% and 19%, respectively. Higher EBV prevalence was found among women with older age, HIV, hrHPV, abnormal cytology, Mycoplasma genitalium infection, smoking habits, younger age at sexual debut, and less frequent condom use. At baseline, women with EBV had a higher prevalence of hrHPV infection than did EBV-negative women (52% vs. 24%; HIV-adjusted PR. Epstein-Barr virus–positive women had a higher prevalence than did EBV-negative women of high-grade precancer (15% vs. 2%) and abnormal cytology (37% vs. 15%), although HIV- and hrHPV-adjusted associations were not significant (high-grade precancer: PR, 2.0 (0.7–5.9) abnormal cytology: PR, 1.4 (0.9–2.2) In prospective analyses, a marginal association was observed between baseline EBV detection and delayed hrHPV clearance. | The data support a possible role for EBV as a high-risk marker or cofactor for HPV-mediated cervical cancer development. |
| Kenya | |||
| N/A | Women (n = 332) with known cervical cytology and hrHPV mRNA results were evaluated for cervical EBV DNA by conventional polymerase chain reaction. | ||
| Female sex workers (FSWs) attending a health clinic | |||
| Islam et al.
| Compare the performance of hr-HPV mRNA testing with dry-A s compared with wet-stored self-collected specimens for detecting high-grade squamous intraepithelial lesion or more severe (⩾HSIL). | High-risk HPV mRNA positivity was higher in sc-WET (36.8%) than sc-DRY samples (31.8%). Prevalence of ⩾ HSIL was 6.9% (10.3% HIV positive, 4.0% HIV negative). Sensitivity of hr-HPV mRNA for detecting ⩾ HSIL was similar in sc-WET (85%; 95% confidence interval (CI) 66%–96%), sc-DRY specimens (78%; 95% CI: 58%–91%), and physician-collected specimens (93%; 95% CI: 76%–99%). Overall, the specificity of hr-HPV mRNA for ⩾ HSIL detection was similar when comparing sc-WET with physician collection. However, specificity was lower for sc-WET (66% (61%–71%) than sc-DRY (71% (66%–76%) Women preferred sc-DRY specimen collection (46.1%) compared with sc-WET (31.1%). However, more women preferred physician collection (63.9%) compared with self-collection (36.1%). | Self-collected stored-dry specimens seemed to perform similarly to sc-WET for the detection of ⩾ HSIL, and could assist in screening. |
| Kenya | |||
| Participants provided 2 self-collected specimens: One stored dry (sc-DRY) using a Viba brush (Rovers) and one stored wet (sc-WET) with Aptima media (Hologic) using an Evalyn brush (Rovers). Physician-collected specimens were collected for HPV mRNA testing (Aptima) and conventional cytology. We estimated test characteristics for each hr-HPV screening method using conventional cytology as the reference standard (⩾ HSIL detection). We also examined participant preference for sc-DRY and sc-WET collection. | |||
| 400 female sex workers in Kenya participated (2013-2018), of which 50% were HIV positive based on enrolment procedures | |||
| Luchters et al.
| Assess the prevalence of high-risk HPV types and HIV among FSW, and the associations between these infections and with other demographic and behavioural variables. Additionally, the complex inter-relationships between type-specific HPV viral load, HIV infection and cervical cytology are evaluated. | Median age of the 820 participants was 28 years (inter-quartile range (IQR) = 24–36 years). One third of women were HIV infected (283/803; 35.2%) and these women were y more likely to have abnormal cervical cytology than HIV-negative women (27%, 73/269, versus 8%, 42/503; P < 0.001). Of HIV-infected women, 73.3% had high-risk HPV (200/273) and 35.5% had HPV 16 and/or 18 (97/273). Corresponding figures for HIV-negative women were 45.5% (229/503) and 15.7% (79/503). After adjusting for age, number of children and condom use, high-risk HPV was 3.6 fold more common in HIV-infected women (95% CI = 2.6–5.1). Prevalence of all 15 of the high-risk HPV types measured was higher among HIV-infected women, between 1.4 and 5.5 fold. Median total HPV viral load was 881 copies/cell in HIV-infected women (IQR = 33–12,110 copies/cell) and 48 copies/cell in HIV-uninfected women (IQR = 6-756 copies/cell; P < 0.001). HPV 16 and/or HPV 18 were identified in 42.7% of LSIL (32/75) and 42.3% of HSIL (11/26) lesions (P = 0.98). High-risk HPV types other than 16 and 18 were common in LSIL (74.7%; 56/75) and HSIL (84.6%; 22/26), even higher among HIV-infected women. HIV-infected sex workers had almost four-fold higher prevalence of high-risk HPV, raised viral load and more precancerous lesions. HPV 16 and HPV 18, preventable with current vaccines, were associated with cervical disease, though other high-risk types were commoner. | Given the common occurrence of high-grade cervical lesions, especially in HIV-infected women, regular HPV screening and follow-up is essential for prevention of cervical cancer. Additional prevention measures, especially higher population-level coverage with HPV vaccine, are required. Current efforts to prevent HIV and HPV are inadequate. New interventions are required and improved implementation of existing strategies. |
| Kenya | |||
| N/A | A cross-sectional community-based survey in Mombasa, Kenya, enrolled 820 female sex workers using snowball sampling. After interview and a gynaecological examination, blood and cervical cytology samples were taken. Quantitative real-time PCR detected HPV types and viral load measures. Prevalence of high-risk HPV was compared between HIV-infected and -uninfected women, and in women with abnormal cervical cytology, measured using conventional Pap smears. | ||
| FSWs | |||
| Menon et al.
| Assess the prevalence of pHR and HR HPV genotypes, BV, TV, and Candida, the most important STIs in FSW women undergoing cervical cancer screening in a private clinic, and explore associations between HR HPV genotypes and these vaginal microbiota. | Of the FSW, 33.3% had HIV and 57.7% harboured a potential HR and HR HPV genotype. The 2 most prevalent potential HR and HR genotypes were HPV 16 (16.10%) and HPV 59 (12.20%). BV was the most common infection (48.3%), followed by | The results underscore the need for enhanced STI management within the framework of cervical cancer prevention |
| Kenya | |||
| N/A | Clinical data | ||
| FSWs | |||
| Menon et al.
| Explore the epidemiology of abnormal cytology and the pairing of pHR/HPV genotypes in HIV-negative and HIV-infected FSW. | Of the 599 FSW who underwent cytological examination, 87 had abnormal cytology (14.5%; 95% CI: 12.0%–17.6%). A combined prevalence of HPV16% and 18 (29.6%; 95% CI: 22.2%–37.8%) was observed in abnormal cytology. HPV 53 and 51 were the most observed pairing in FSW with abnormal cytology. Significant adjusted associations were found between abnormal cytology and | The strong association between TV and cervical dysplasia and the high percentage of FSW harbouring more than one STI underscore the need for enhanced STI management within the framework of cervical cancer prevention. |
| Kenya | |||
| N/A | Structured questionnaire; testing for HIV and HPV; cervical samples | ||
| FSWs | |||
| Muluneh et al.
| Identify predictors for cervical cancer screening service utilization. | Cervical cancer screening utilization was associated with providers’ recommendation (AOR = 6.8; 95% CI: 2.3, 9.7), history of sexually transmitted infection (AOR = 6.9; 95% CI: 1.29, 7.2), frequency of facility visit (AOR = 4.8; 95% CI: 1.97, 11.8) and history of vaginal examination (AOR = 0.21; 95% CI: 0.1, 0.68). | Guidelines that promote integration of the screening service to the routine care and treatment (opportunistic screening) should be developed and implemented. Assigning a female cervical cancer screener and availing convenient clinic times should also be given due emphasis by the ministry and sector health offices. |
| Ethiopia | |||
| N/A | Questionnaire | ||
| Sex workers attending sex workers’ confidential clinic | |||
| Namale et al.
| Report one-year experiences of visual inspection with acetic acid (VIA) positivity among FSWs in the early detection of pre-cancerous and cancerous cervical lesions | Of 842 women assessed for eligibility, 719 (85 %) of median age 30 (IQR 26, 35) were screened, and 40 (6 %) women were VIA positive. Of the 24 histology specimens analysed, 6 showed inflammation, only 1 showed cervical intraepithelial neoplasia (CIN) 1, 13 women showed CIN2/3, while 4 women already had invasive cervical cancer. The overall prevalence of HIV was 43 %, of whom only 35 % were receiving ART. In the age-adjusted analysis, VIA positivity was more likely among women who reported having > 100 lifetime partners, and HIV positive women. | A relatively low proportion of VIA positivity was found in this population. The experience from this programme implies that the VIA results are poorly reproducible even among a category of trained professional health workers. Interventions for improving cervical cancer screening should be recommended as part of HIV care for FSWs to reduce the disease burden in this population. |
| Uganda | |||
| The women were screened using the VIA method (application of 3–5 % acetic acid to the cervix). All VIA positive women were referred to a tertiary hospital for colposcopy, biopsy, and immediate treatment (if indicated) at the same visit according to national guidelines. Data on socio-demographic, sexual behaviour, sexual reproductive health and clinical characteristics were collected. | |||
| FSWs attending the Good Health for Women Project (GHWP) clinic | |||
| Patel et al.
| Estimate type-specific prevalence of human papillomavirus (HPV) and examined risk factors for abnormal cervical cytology among female sex workers | Over half (54%) were infected with a high-risk (HR) HPV type, of which HPV16 and 52 were the most common types. HIV-1 prevalence was 23% and HIV-1 sero-positivity was associated with high-grade cervical lesions, particularly among women with CD4 count less than 500 cells/mm3 (odds ratio (OR) = 6.9; 95% confidence interval (CI) 1.7–24.9). Among women who had normal cytology at the time of entry into the study, the risk of having an abnormal Pap smear within one year was significantly elevated for women with multiple HPV types at study entry (adjusted odds ratio (aOR) = 6.0; 95% CI: 2.3–15.7) and with a subset of HR HPV types (aOR = 4.2; 95% CI: 1.6–11.2). Detection of multiple concurrent HPV infections may be a useful marker to identify women at risk of developing precancerous lesions in populations of high HPV prevalence. | Detection of multiple concurrent HPV infections may be a useful marker to identify women at risk of developing precancerous lesions in populations of high HPV prevalence. |
| Kenya | |||
| N/A | Results of HPV tests and PAP smears | ||
| FSWs | |||
| Senkomago et al.
| Report longitudinal results from a cohort of FSWs, comparing hrHPV-RNA testing of physician- and self-collected specimens for the detection of high-grade squamous intraepithelial lesions or higher grade lesions (HSIL+) over 24 months. | Overall, 350 FSWs aged 18–50 years participated. hrHPV-RNA prevalence decreased slightly from 29.9% (103/344) at baseline to 24.3% (53/218) at 24 months for physician-collected, and 28.5% (98/344) to 24.3% (53/218) for self-collected specimens. Agreement between the sampling methods appeared to increase over time (baseline κ 0.55, 95% confidence interval (CI) 0.45–0.65; 24 months κ 0.83, 95% CI: 0.74–0.91). Among 21 patients with HSIL + over 24 months, 18 (86%) and 17 (81%) had hrHPV-RNA-positive results at baseline in physician-and self-collected specimens, respectively; and 20 (95%) had baseline hrHPV-RNA-positive results or cytology anomalies. Overall agreement between physician-and self-collected hrHPV-RNA results was moderate and appeared to increase over time. Baseline physician-and self-collected hrHPV-RNA tests were similarly strong indicators of cumulative HSIL+ over 24 months | These data support the use of hrHPV-RNA testing as a primary screening strategy in resource-limited regions where cytology is largely not available for screening, as long as women with hrHPV-RNA positive results can be assured of appropriate follow-up and treatment. Self-collection has also been shown to be an acceptable practice among women in Sub-Sahara Africa. |
| Kenya | |||
| N/A | Self-collected cervico-vaginal specimens for hrHPV-RNA testing, and a physician collected cervical specimens for hrHPV-RNA testing and conventional cytology. hrHPV-RNA testing was conducted every 3 months, and conventional cytology every 6 months. | ||
| FSWs who were aged at least 18 years, were not in the second or third trimester of pregnancy, and had an intact cervix. | |||
| Smith et al.
| Estimate human papillomavirus (HPV) prevalence and type distribution among 90 female sex workers (FSWs) aged 18 to 58 years | The HPV prevalence in exfoliated cervical cell specimens was 36.7%. The most common HPV types found were HPV-52 (11.1%), HPV-31 and -39 (each at 5.6%), and HPV-16 and -83 (each at 3.3%). The prevalence of low-grade squamous intraepithelial lesions was 3.3%, and that of atypical squamous cells of undetermined significance was 18.9%. No high-grade lesion was found. Although associations were imprecise, the HPV prevalence was higher among women who reported younger age at the first intercourse, contraceptive use, a history of cervical lesions, and no history of condom use. | The prevalence rates of HPV and cervical lesions among FSWs in Madagascar appear higher than among FSW populations from other African countries with a relatively higher population-based prevalence of human immunodeficiency virus infection. |
| Madagascar | |||
| N/A | Information on sexual and behavioural characteristics was obtained via a questionnaire. Exfoliated cervical cell specimens were collected for conventional cytologic examination and HPV DNA testing by polymerase chain reaction. | ||
| FSWs | |||
| Sweet et al.
| Characterize the baseline prevalence, incidence, and genotype distribution of HPV infection in 348 female sex workers (FSWs) using a highly sensitive, type-specific DNA assay; examine the burden of HPV and HPV-associated cervical disease, stratified by HIV-serostatus | Baseline HPV prevalence was 23.6% for any HPV and 20.4% for high-risk HPV (hrHPV) types. Most prevalent types were HPV52 (10.1%), HPV35 (2.3%), and HPV51 (2.3%). A quarter (24%) of participants were HIV-positive. HPV prevalence was higher in HIV-positive (32.1%) than HIV-negative (20.8%) participants. hrHPV prevalence was higher in HIV-positive (27.4%) than HIV-negative (18.2%) women. During follow-up, HPV IR was 31.4 (95% CI: 23.8–41.5) for any HPV and 24.2 (95% CI: 17.9–32.8) for hrHPV types. HPV52 had the highest IR (6.0; 95% CI: 6.5–10.3). Overall HPV and hrHPV prevalence were lower than expected, but both prevalence and incidence were higher in HIV-positive than in HIV-negative women. | The higher prevalence and incidence of HPV, and associated high-grade cervical disease observed in HIV-positive women indicates that HIV-positive women should be a priority for public health interventions to reduce ICC morbidity and mortality. Prevention strategies, including HPV vaccination, the screening and treatment of cervical precancerous lesions, are critically needed globally to prevent ICC in both HIV-positive and HIV-negative women. |
| Kenya | |||
| N/A | Specimens for HPV testing were collected every three months and cervical specimens for cytology examinations were collected every six months. | ||
| FSWs | |||
| Ting et al.
| Compare the performance of hrHPV mRNA testing of physician- and self-collected specimens for detecting cytological high-grade squamous intraepithelial lesions or more severe (QHSIL); and examined risk factors for hrHPV mRNA positivity in female sex workers in Nairobi. | Overall hrHPV mRNA prevalence was similar in physician- and self-collected specimens (30% vs. 29%). Prevalence of QHSIL was 4% (n = 15). Overall sensitivity of hrHPV testing for detecting QHSIL was similar in physician-collected (86%; 95% CI, 62%–98%; 13 cases detected) and self-collected specimens (79%; 95% CI, 55%–95%; 12 cases detected). Overall specificity of hrHPV mRNA for QHSIL was similar in both physician-collected (73%; 95% CI: 68%–79%) and self-collected (75%; 95% CI: 70%–79%) specimens. High-risk HPV mRNA positivity in both physician- and self-collected specimens seemed higher in women who were younger (G30 years), had | hrHPV self-testing have high NPV and have the potential to effectively identify women at higher risk for high-grade lesions without an initial gynaecologic examination. Limited resources may then be channelled into clinical follow-up (e.g., rescreening using a different test) of a woman who was positive by AHPV self-testing, based on specific local capacity. |
| Kenya | |||
| N/A | Women self-collected a cervicovaginal specimen. A physician conducted a pelvic examination to obtain a cervical specimen. Physician- and self-collected specimens were tested for hrHPV mRNA and sexually transmitted infections using APTIMA nucleic acid amplification assays (Hologic/Gen-Probe Incorporated, San Diego, CA). Cervical cytology was conducted using physician-collected specimens and classified according to the Bethesda criteria. | ||
| FSWs |